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that stabilizes the disease and reduces hospitalizations will help
patients and payers as well.
PMH44
THE PREDICTIVE VALIDITY OF DIFFERENT ADHERENCE
MEASURES USING ADMINISTRATIVE CLAIMS DATA
Karve SJ, Martin BC
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: To determine the predictive validity of eight dif-
ferent adherence measures by studying the variability explained
between each measure and two outcome measures: hospitaliza-
tion episodes and total non-pharmacy cost. METHODS: This
study was a retrospective analysis of the Arkansas Medicaid
administrative claims data. Schizophrenia (ICD-9-CM = 295.**)
patients were identiﬁed in the recruitment period July 2000
through April 2004. Patients had to be >18 years old, have pre-
scription beneﬁts, and continuously eligible for 6 months prior
and 24 months after their ﬁrst antipsychotic prescription.
Persons taking two different antipsychotic drug products simul-
taneously were excluded. Medication Possession Ratio (MPR),
Proportion Of days Covered (PDC), Medication Possession
Ratio, modiﬁed (MPRm), Reﬁll Compliance Rate (RCR), Com-
pliance Ratio (CR), Continuous Measure of Medication Gaps
(CMG), Days Between Fills Adherence Rate (DBR), and Con-
tinuous, Single Interval Measure of Medication Acquisition
(CSA) were computed and modeled to predict hospitalizations
and non-pharmacy costs. RESULTS: A total of 3971 patients
with a mean age 46.5 years, 54% were female, 55% were white,
and 38% were black. The one-year adherence rates were numer-
ically similar for MPR (0.74 SD = 0.31) and PDC (0.72, SD =
0.29). Other measures such as MPRm (82.21%, SD = 27.27),
RCR (97.20% SD = 115.05), CR (81.39% SD = 64.18) DBR
(97.20% SD = 115.05) and CSA (0.95 SD = 0.79) had higher
adherence values. The partial R-squares of the multivariate
regression models will be reported. CONCLUSION: There is
considerable variability in rates of adherence among the 8 mea-
sures of adherence. MPR and PDC which used the entire study
period as the denominator had the most conservative adherence
values. In contrast MPRm, PDC, RCR, CR, DBR which only
consider the time between ﬁrst and last prescription ﬁll dates esti-
mate higher levels of adherence.
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OBJECTIVES: The pharmaco-economic evaluation of treatment
for Alzheimer’s Disease (AD) has relied on general measures of
utilities that have been validated in general populations. There
has been little study of the relationship between disease speciﬁc
measures of health status, functional capacity and/or quality of
life in AD and measures of Quality Adjusted Life Years (QALYs),
the outcome of primary interest in pharmaco-economic assess-
ments. METHODS: Follow-up data were obtained from care-
giver proxy raters at 3, 6, and 9 months concerning 421 patients
with early stage Alzheimers Disease, living with at least one care-
giver in a non-institutional setting, who participated in the
CATIE AD trial of antipsychotic medication for psychosis or
aggression due to AD. Multiple regression models were used to
examine the relationship between change in the Health Utilities
Index (HUI)—Mark III, and a broad range of socio-demographic
characteristics, psychiatric symptoms, cognitive performance,
activities of daily living, and AD-related quality of life—to deter-
mine the measures that were most strongly related to QALYs 
and the power of clinical measures to predict utility scores.
RESULTS: Analysis of correlates of change in utilities scores
from baseline showed weak bivariate, and for the most part,
non-signiﬁcant multivariate relationships between change in
health utility scores and measures of socio-demographic charac-
teristics, psychiatric symptoms, and cognitive performance.
However, there were highly signiﬁcant associations between
decreases in health utilities and change two scales: the AD Coop-
erative Study Scale for Activities of Daily Living (ADCS-ADL)
and AD-Related Quality of Life (ADRQoL) (both p < 0.001).
The total R-squared was 17%. CONCLUSION: Only weak rela-
tionships were found between changes in a standard measure of
health utilities and socio-demographic and clinical indicators.
The presence of signiﬁcant cognitive impairment and the need to
rely on proxy raters may limit the validity of utility measurement
in AD.
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NOVEL USE OF A TELEPHONE BASED INTERACTIVE VOICE
RESPONSE SYSTEM TO IMPROVE DATA COLLECTION
Pierce J,Wenzel K
ClinPhone, East Windsor, NJ, USA
OBJECTIVES: To investigate whether electronic memory aids
and IVR verbal numeric scales improve the quality of data col-
lection methods. To evaluate whether perceptions of clinical
change reported directly by the patient is enhanced by the use of
a novel telephone based interactive voice response system.
METHODS: A total of 137 patients from a multi-site, double-
blind, placebo controlled study were administered the IVR 
PGI-I and the Memory Enhanced Retrospective Evaluation 
of Treatment (MERET) over a 4-week period. Effect sizes using
these approaches were determined and compared to determine
any differences. In addition, we investigated whether dosage level
predicted a more rapid onset of action. RESULTS: At 2 and 4
weeks the point estimates for both IVR PGI-I and MERET were
2.68 and 3.24 (p = 0.035) and 2.5 and 3.21 (p = 0.015), respec-
tively. Overall, the effect size for the PGI-I was 0.526 compared
to 0.612 for MERET. For the subjects in the higher dose group,
there were signiﬁcant improvements reported by the patient at 1
day for shoulder (p = 0.008) and back pain (p = 0.01). Signiﬁ-
cant differences were also found at day 3 for pain while awake
(p = 0.03), day 5 for Global emotional improvement (p = 0.03),
and day 7 and Global physical improvement (p = 0.04) at day
7. No other signiﬁcant differences were found. CONCLUSION:
The use of an electronic memory aid produced a 16.3% larger
drug-placebo treatment effect size compared to the standard
PGI-I. MERET ratings increased the patients’ perception on the
effectiveness of active drug treatment with minimal inﬂuence of
the placebo effect. In this study, the higher dose had an earlier
onset of efﬁcacy for both physical and emotional symptoms. The
daily IVR reporting of this data allowed detection of a rapid
onset of action.
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THE EFFECTS OF PATIENT TYPE ON PHYSICAL AND MENTAL
HEALTH OF CAREGIVERS IN FRANCE, GERMANY, ITALY,
SPAIN AND THE UNITED KINGDOM
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OBJECTIVES: To assess the effects of caring for adult patients
with chronic conditions on the physical and mental health of
caregivers. METHODS: This analysis was based on data from
